Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
25 July 2019Website:
http://castlebiosciences.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 6 min agoDividend
Analysts recommendations
Institutional Ownership
CSTL Latest News
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's founder, president & CEO, Derek Maetzold, has been named an EY 2024 Entrepreneur Of The Year® for the Gulf South region.
Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASCO--Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting, May 31-June 4, 2024.
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Castle Biosciences (CSTL) may be a good option for investors seeking to take advantage of the recent price trend in strong stocks. It is among the stocks that have met our criteria for shorter-term trading strategies.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET featuring Camilla Zuckero, Derek Maetzold, and Frank Stokes. Conference Call Participants include Subbu Nambi, Kyle Mikson, Corey Rosenbaum, Thomas Flaten, Paul Knight, Mason Carrico, and Catherine Schulte. The call is being recorded.
Castle Biosciences, Inc. reported a quarterly loss of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This is an improvement from the loss of $1.10 per share reported a year ago.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meeting.
Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript
- 1(current)
What type of business is Castle Biosciences?
Castle Biosciences, Inc. is a company focused on treating dermatologic cancers at the commercial stage. The company is dedicated to providing physicians and their patients with personalized, clinically meaningful genomic information to make more accurate treatment decisions. The company has two patented products on the market, DecisionDx-Melanoma and DecisionDx-UM, as well as two active proprietary products in development: DecisionDx-UM and DecisionDx-Melanoma. The company develops treatment plans for certain types of cancer taking into account clinical and pathological factors. Its flagship product, DecisionDx-Melanoma, is a patented gene expression profile (GEP) test that predicts the risk of metastasis or recurrence in patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. The company was founded in 2007 and is headquartered in Friendswood, Texas.
What sector is Castle Biosciences in?
Castle Biosciences is in the Healthcare sector
What industry is Castle Biosciences in?
Castle Biosciences is in the Diagnostics & Research industry
What country is Castle Biosciences from?
Castle Biosciences is headquartered in United States
When did Castle Biosciences go public?
Castle Biosciences initial public offering (IPO) was on 25 July 2019
What is Castle Biosciences website?
https://castlebiosciences.com
Is Castle Biosciences in the S&P 500?
No, Castle Biosciences is not included in the S&P 500 index
Is Castle Biosciences in the NASDAQ 100?
No, Castle Biosciences is not included in the NASDAQ 100 index
Is Castle Biosciences in the Dow Jones?
No, Castle Biosciences is not included in the Dow Jones index
When does Castle Biosciences report earnings?
The next expected earnings date for Castle Biosciences is 02 August 2024